AnaptysBio (ANAB) had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a "buy" rating on the stock.
AnaptysBio (ANAB) had its price target raised by Wedbush from $60.00 to $75.00. They now have an "outperform" rating on the stock.
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible [Yahoo! Finance]
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
AnaptysBio (ANAB) was given a new $50.00 price target by Truist Financial Corporation.